Treatment of favourable-risk metastatic kidney cancer

The treatment of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC) has been dramatically changed with the introduction of immune checkpoint inhibitors (immunotherapy) as a first-line of treatment after surgery. However, it is less clear whether immunotherapy benefits patients with favourable-risk disease in the same way. A debate between experts at the International […]

read more

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]

read more

The effect of antibiotic use on outcomes with kidney cancer drug treatments

A recent study has looked at the use of antibiotics with systemic drug treatments for renal cell carcinoma (RCC). The study investigated patients taking immune checkpoint inhibitors (146 patients), interferon-α (510 patients), mTOR inhibitors (660 patients) and VEGF targeted therapies (2,974 patients). The latter three groups were on phase II/III clinical trials, while the immunotherapy […]

read more

Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer

This study, published in European Urology Oncology this week, investigated the impact of antibiotic use on clinical outcomes in patients with metastatic renal cell carcinoma (RCC) treated with systemic anti-cancer drugs. The use of antibiotics alters the microbes living in our guts (gut microbiota), which is a key regulator of immune system. In the study, […]

read more

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab plus axitinib in untreated patients with advanced renal cell carcinoma (RCC) with sarcomatoid characteristics were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid RCC is an uncommon but highly aggressive form of RCC, which tends to have […]

read more

Outcomes of metastatic kidney cancer patients treated with first-line immunotherapy and second-line VEGFR-TKI

The standard of care recommended for the treatment of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC) is first-line immune checkpoint inhibitor therapy (nivolumab plus ipilimumab), followed by a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) in the second-line (axitinib, cabozantinib). A recent study published in European Journal of Cancer reviewed data […]

read more

Long term survival of patients with metastatic kidney cancer – a real world study

This real world study reports on the long term survival of patients with metastatic renal cell carcinoma (RCC) who have taken 1 to 4 lines of systemic drug treatment sequentially under real life conditions. Patients were treated according to their prognostic score (good, intermediate, poor). Overall survival was 57 months in patients with good or intermediate […]

read more

Low PD-L1 associated with long term response to sunitinib

Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here

read more

ASCO 2019: First-line immunotherapy combinations in metastatic kidney cancer

This presentation from the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week, reviews the evidence for the efficacy of immunotherapy combinations for the treatment of metastatic renal cell carcinoma (RCC). The authors concluded that immunotherapy-VEGF inhibitor combinations have similar effectiveness as combinations of immunotherapy drugs, and there does not […]

read more

ASCO 2019: Analysis of CARMENA trial results using IMDC risk groups

The results from CARMENA, a randomised phase III clinical trial to assess the importance of surgery to remove the kidney (nephrectomy) in people with metastatic kidney cancer, have been re-analysed and were presented at the 2019 American Society of Clinical Oncology (ACSO) annual meeting in Chicago this week. The original results showed that many people with […]

read more
Showing 1 to 10 of 28 results
  TOP